IGM Biosciences 관리

관리 기준 확인 2/4

IGM Biosciences CEO는 Mary Harler, Oct2024 에 임명되었습니다 의 임기는 1년 미만입니다. 는 $ 3.10M 가치에 해당하는 회사 주식의 0.59% 직접 소유합니다. 3.10M. 경영진과 이사회의 평균 재임 기간은 각각 3 년과 6 년입니다.

주요 정보

Mary Harler

최고 경영자

n/a

총 보상

CEO 급여 비율	n/a
CEO 임기	less than a year
CEO 소유권	0.6%
경영진 평균 재임 기간	3yrs
이사회 평균 재임 기간	6yrs

최근 관리 업데이트

Recent updates

Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation

Jan 05

IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business

Sep 23

IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates

Aug 29

IGM Biosciences GAAP EPS of -$1.33 misses by $0.93, revenue of $0.4M

Aug 08

We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate

Jun 09

IGM Biosciences: Interesting Science, Poor Trial Data

Feb 23

Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Deliver On Growth Plans?

Feb 17

Here's Why We're Not Too Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation

Sep 07

IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans

May 25

CEO

Mary Harler (59 yo)

less than a year

테뉴어

Ms. Mary Beth Harler, M.D. is the Chief Executive Officer of IGM Biosciences, Inc. since October 01, 2024 and serves as its Director. She had been Head of Research & Autoimmunity at IGM Biosciences, Inc. s...

리더십 팀

이름	위치	테뉴어	보상	소유권
Mary Harler	CEO & Director	less than a year	데이터 없음	0.59% $ 3.1m
Misbah Tahir	Chief Financial Officer	5.8yrs	US$1.08m	0.035% $ 186.3k
TS Harigopal	Senior Vice President of Group Operations	1.8yrs	데이터 없음	데이터 없음
Steven Weber	Senior VP	2.7yrs	데이터 없음	0.0043% $ 22.9k
Paul Graffagnino	Senior Vice President of Legal Affairs	3.8yrs	데이터 없음	데이터 없음
Suzette Tauber	Chief Human Resources Officer	5.4yrs	데이터 없음	데이터 없음
Angus Sinclair	Executive Vice President of Research	3.3yrs	데이터 없음	데이터 없음
Lisa Decker	Chief Business Officer	3.7yrs	US$4.92m	0.030% $ 160.1k
Marvin Peterson	Executive Vice President of Process Development & Manufacturing	3.6yrs	데이터 없음	데이터 없음
Elizabeth Haanes	Senior Vice President of Intellectual Property	2.6yrs	데이터 없음	데이터 없음
Elaine Sapinoso	Senior Vice President of Quality	1.8yrs	데이터 없음	데이터 없음
Faraz Siddiqui	Senior Vice President of Manufacturing Operations	1.3yrs	데이터 없음	데이터 없음

3.0yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 관리: IGMS 의 관리팀은 경험 ( 3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Mary Harler	CEO & Director	no data	데이터 없음	0.59% $ 3.1m
Felix Baker	Independent Director	3.8yrs	US$168.55k	0.0037% $ 19.7k
M. Behrens	Independent Director	5.8yrs	US$178.30k	0.68% $ 3.6m
Mark Davis	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Rafi Ahmed	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Michael Lee	Independent Director	5.3yrs	US$166.09k	0.016% $ 82.9k
Jakob Topsoe	Independent Director	6.3yrs	US$166.09k	0.15% $ 785.2k
Julie Hambleton	Independent Director	6.3yrs	US$204.09k	0.0034% $ 17.8k
Christina Topsoe	Independent Director	6.3yrs	US$175.84k	0.099% $ 522.6k
William Strohl	Independent Director	6.3yrs	US$236.59k	0% $ 0
Elizabeth Thompson	Independent Director	1.1yrs	US$167.54k	0.0073% $ 38.7k
Gordon J. Freeman	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음

6.0yrs

평균 재임 기간

55yo

평균 연령

경험이 풍부한 이사회: IGMS 의 이사회는 경험(평균 재직 기간 6 년)으로 간주됩니다.

IGM Biosciences 관리

관리 기준 확인 2/4

주요 정보

최근 관리 업데이트

IGM Biosciences, Inc. Announces Chief Executive Officer Changes

Independent Director notifies of intention to sell stock

IGM Biosciences, Inc., Annual General Meeting, Jun 11, 2024

CEO, President & Director recently sold US$90k worth of stock

Insufficient new directors

IGM Biosciences, Inc. Announces Board Changes

Recent updates

Consensus revenue estimates increase by 16%, EPS downgraded

Third quarter 2024 earnings: Revenues exceed analysts expectations while EPS lags behind

We're Not Very Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate

Consensus revenue estimates decrease by 74%

Price target decreased by 13% to US$19.10

IGM Biosciences, Inc. Announces Chief Executive Officer Changes

IGM Biosciences: Waiting For Godot

Consensus revenue estimates increase by 281%

Consensus revenue estimates fall by 95%

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

IGM Biosciences, Inc. Provides Pipeline Updates

Independent Director notifies of intention to sell stock

Consensus revenue estimates increase by 15%

Consensus revenue estimates increase by 1,210%

IGM Biosciences: Unlikely To Move The Needle Again In 2024

First quarter 2024 earnings released: US$0.83 loss per share (vs US$1.33 loss in 1Q 2023)

IGM Biosciences, Inc. Provides Revenue Guidance for the Second Quarter and Full Year 2024

Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Invest In Growth?

IGM Biosciences, Inc., Annual General Meeting, Jun 11, 2024

New major risk - Share price stability

CEO, President & Director recently sold US$90k worth of stock

Consensus EPS estimates upgraded to US$3.26 loss

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

IGM Biosciences: Imvotamab Data 2nd Half Of 2024 With Other Inflection Points

Igm Biosciences, Inc. to Reduce its Workforce by Approximately 22%

Consensus revenue estimates decrease by 13%, EPS upgraded

We Think IGM Biosciences (NASDAQ:IGMS) Needs To Drive Business Growth Carefully

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

New major risk - Revenue and earnings growth

IGM Biosciences, Inc. Announces Board Changes

Price target decreased by 7.8% to US$30.09

New minor risk - Shareholder dilution

IGM Biosciences, Inc. announced a financing transaction

IGM Biosciences, Inc. Announces FDA Clearance to Begin Clinical Studies of Imvotamab in Lupus and Rheumatoid Arthritis

Consensus revenue estimates decrease by 43%, EPS upgraded

We're Not Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn

Consensus revenue estimates decrease by 50%

Price target decreased by 17% to US$32.64

IGM Biosciences Initiates First-In-Human Clinical Trial of Igm-7354 in Solid Tumors

IGM Biosciences Announces Update on Igm-8444 Phase 1 Trial and Future Clinical Development

Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation

CEO, President & Director recently sold US$235k worth of stock

CEO, President & Director notifies of intention to sell stock

Independent Director recently bought US$1.0m worth of stock

Insufficient new directors

Independent Director recently bought US$1.0m worth of stock

Chief Scientific Officer exercised options and sold US$548k worth of stock

Independent Chairman of the Board recently bought US$140k worth of stock

IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business

Chief Scientific Officer exercised options and sold US$460k worth of stock

IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates

Chief Scientific Officer exercised options and sold US$531k worth of stock

Price target decreased to US$43.78

Consensus revenue estimates fall by 98%

IGM Biosciences GAAP EPS of -$1.33 misses by $0.93, revenue of $0.4M

Insufficient new directors

We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate

IGM Biosciences, Inc. Appoints Steven Weber as Principal Accounting Officer

Independent Director recently bought US$234k worth of stock

Consensus revenue estimates fall by 86%

Price target decreased to US$52.78

Chief Scientific Officer exercised options and sold US$60k worth of stock

Independent Director recently bought US$1.4m worth of stock

Price target decreased to US$52.78

Chief Scientific Officer exercised options and sold US$207k worth of stock

Price target decreased to US$57.89

IGM Biosciences: Interesting Science, Poor Trial Data

Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Deliver On Growth Plans?